Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous(SC) Ustekinumab Maintenance in Pediatric Participants with Moderately to Severely Active Crohn’s Disease

The primary objective and primary endpoint in this study is to assess clinical remission.  To evaluate the efficacy of ustekinumab dosing in maintaining clinical remission among participants who were in clinical response in induction.  To evaluate the safety profile of ustekinumab.  To evaluate ustekinumab exposure (pharmacokinetics [PK]).  To evaluate the efficacy of IV ustekinumab during the induction period.  To evaluate the efficacy of SC ustekinumab during the maintenance period among participants who were in clinical response in induction.

Participants who meet inclusion criteria will receive ustekinumab through an IntraVenous infusion during the induction period. And then will be randomized either every 8weeks or 12weeks to receive ustekinumab through a SubCutaneous injection.

Marc Schaefer
Erica Miller - at or 717-531-5656

Younger than 18 years old
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 2 to 18years at the time of the first administration of study drug
Must have been diagnosed with moderately to severely active Crohn's Disease prior to screening

Exclusion Criteria:
Has had any kind of bowel resection within 6months
Currently has or is suspected to have an abscess
Digestive Systems & Liver Disease
I'm interested
Share via email
See this study on
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,